{"url_path":"/sec/aura/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-11","source_url":"https://www.sec.gov/Archives/edgar/data/1501796/0001193125-26-216808-index.html","accession_number":"0001193125-26-216808","cik":"0001501796","ticker":"AURA","issuer_name":"Aura Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1501796/0001193125-26-216808-index.html","primary_entity_key":"0001501796","primary_entity_name":"Aura Biosciences, Inc."},"word_count":113,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\n(a) Matrix Repurchase\n\nAs previously disclosed, on April 30, 2026, we and Matrix entered into a stock purchase agreement pursuant to which we agreed to repurchase, in a privately negotiated transaction, up to 6,922,870 shares of our common stock held by Matrix. On May 7, 2026, we completed the repurchase of all 6,922,870 shares of our common stock from Matrix.\n\n(c) Insider Trading Arrangements\n\nNone of our directors or officers, as defined in Rule 16a-1(f) under the Securities Act, adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement, as defined in Item 408(c) of Regulation S-K, during the quarter ended March 31, 2026.\n\n77"}